ClinicalTrials.gg

Program

bilastine

Also written as “Bilastine”, “Bilastine oral dispersible tablets” and “Bilaxten oral dispersible tablets”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Conjunctivitis, Allergic · Urticaria · Rhinitis, Allergic · Asthma, led by 4 companies.

Furthest: phase 4, since Jan 9, 200719 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Faes Farma140 open or runningphase 3since Jan 9, 2007Jan 8, 2007none ahead
Menarini Group30 open or runningphase 4since Oct 13, 2015Oct 13, 2015none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Jun 20, 2025Jun 20, 2025none ahead
Yuhan10 open or runningphase 3since Jul 20, 2011Jul 20, 2011none ahead

Also a collaborator on its studies: ORA, dynamic-science-s-l, allied-research-international and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Jan 8, 2007.

  1. Dec 12, 2007Phase 1 study in HealthyFaes Farma · NCT00572611 · 6 enrolled · United Kingdom
  2. Dec 14, 20072 phase 2 studies in Rhinitis, Allergic, SeasonalFaes Farma · NCT00574379, NCT00574210
  3. Mar 4, 2010Phase 2 study in Chronic UrticariaFaes Farma · NCT01081574 · 36 enrolled · Australia, Germany, Sweden
  4. Apr 21, 2010Phase 3 study in Rhinitis, Allergic, SeasonalFaes Farma · NCT01108783 · 720 enrolled
  5. May 13, 2010Phase 1 study in HealthyFaes Farma · NCT01124123 · 12 enrolled · Spain
  6. May 19, 2010Phase 3 study in Rhinitis, Allergic, PerennialFaes Farma · NCT01127620 · 650 enrolled
  7. Jul 20, 2011Yuhan's first study: phase 3 study in Rhinitis, Allergic, SeasonalNew to YuhanYuhan · NCT01400828 · 239 enrolled · Korea, Republic of
  8. Oct 13, 2015Menarini Group's first study: phase 4 study in Rhinitis, AllergicNew to Menarini GroupMenarini Group · NCT02576041 · 19 enrolled · Italy
  9. Apr 28, 2016Phase 4 study in AsthmaMenarini Group · NCT02761252 · 454 enrolled · Croatia, Czechia, Germany and more
  10. Jul 20, 2017Phase 2 study in Conjunctivitis, AllergicFaes Farma · NCT03231969 · 121 enrolled · United States
  11. Mar 21, 2018Phase 3 study in Conjunctivitis, AllergicFaes Farma · NCT03479307 · 228 enrolled · United States
  12. Aug 3, 2018Phase 1 study in PharmacokineticsMenarini Group · NCT03633760 · 24 enrolled · China
  13. Mar 1, 2021Phase 3 study in Conjunctivitis, AllergicFaes Farma · NCT04810390 · 59 enrolled · Spain
  14. Jun 20, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in UrticariaNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07042828 · 42 enrolled · India

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor inverse agonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
desloratadineruleOrganonphase 440
fexofenadineruleSanofiphase 438
DiphenhydramineruleJohnson & Johnsonphase 416

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07042828Urticaria · India1CompletedHumanis Saglık Anonim SirketiJun 16, 202542
NCT04810390Conjunctivitis, Allergic · Spain3CompletedFaes FarmaNov 30, 202259
NCT03633760Pharmacokinetics · China1UNKNOWNMenarini GroupApr 30, 201924
NCT03479307Conjunctivitis, Allergic · United States3CompletedFaes FarmaAug 9, 2018228
NCT03231969Conjunctivitis, Allergic · United States2CompletedFaes FarmaOct 11, 2017121
NCT02761252Asthma · Croatia, Czechia, Germany and more4CompletedMenarini GroupNov 24, 2016454
NCT02576041Rhinitis, Allergic · Italy4CompletedMenarini GroupDec 201519
NCT01400828Rhinitis, Allergic, Seasonal · Korea, Republic of3CompletedYuhanJun 2013239
NCT01127620Rhinitis, Allergic, Perennial3CompletedFaes FarmaMar 2006650
NCT01124123Healthy · Spain1CompletedFaes FarmaJun 201012
NCT01108783Rhinitis, Allergic, Seasonal3CompletedFaes FarmaAug 2003720
NCT01081574Chronic Urticaria · Australia, Germany, Sweden2CompletedFaes FarmaJun 201236
NCT00574379Rhinitis, Allergic, Seasonal · United States2CompletedFaes FarmaMar 2008805
NCT00574210Rhinitis, Allergic, Seasonal · Canada2CompletedFaes FarmaFeb 2008502
NCT00572611Healthy · United Kingdom1CompletedFaes FarmaDec 20076
NCT00504933Rhinitis, Allergic, Seasonal3CompletedFaes FarmaNov 2005683
NCT00421109Urticaria · Argentina, Belgium, France and more3CompletedFaes FarmaJul 2007522
NCT00420082Rhinitis, Allergic, Seasonal · Austria2CompletedFaes Farma75
NCT00419783Rhinitis, Allergic · United States1CompletedFaes FarmaDec 200630

How it is read

Names in the registry

  • “Bilastine”, 13 entries
  • “bilastine”, 2 entries
  • “Bilastine oral dispersible tablets”, 1 entry
  • “Bilaxten oral dispersible tablets”, 1 entry
  • “Bilastine 0.2%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.